Prostatic Acid Phosphatase (PAP) Test
The PAP test measures serum prostatic acid phosphatase, an enzyme secreted by prostatic epithelial cells. Though largely supplanted by PSA, it retains value in metastatic castration-resistant prostate cancer and when PSA is therapeutically suppressed. PAP is labile and sensitive to prostatic manipulation; it is interpreted with PSA, imaging, and clinical context.
1
Biomarkers
Blood (serum)
Sample
2–4 business days
Turnaround
No
Fasting
What is the PAP test?
The Prostatic Acid Phosphatase (PAP) Test measures serum activity or concentration of an enzyme secreted by prostatic epithelial cells. Although it has been largely replaced by prostate-specific antigen for initial detection and monitoring of prostate cancer, PAP offers distinct value in selected scenarios: metastatic or castration-resistant disease where PSA may be therapeutically suppressed, correlation with bone metastases, and assessment of high-grade or poorly differentiated tumours that may produce less PSA. Practitioners order PAP when managing advanced prostate cancer under androgen blockade, when PSA alone does not capture disease activity, or when a historical baseline exists and continuity of monitoring is desired. It is not a first-line screening test and should be interpreted within the broader clinical picture of imaging, histology, and other biochemical markers.
What does the PAP test measure?
Prostatic acid phosphatase is a glycoprotein enzyme secreted by prostatic epithelial cells, with high concentrations in prostatic tissue and seminal fluid. Small amounts circulate in serum under normal conditions. When prostatic architecture is disrupted — by malignancy, inflammation, or instrumentation — larger quantities enter the bloodstream. PAP has a shorter circulating half-life than prostate-specific antigen and is less stable in vitro, requiring careful specimen handling.
PAP was the first widely used tumour marker for prostate cancer and remains valuable in specific contexts despite being largely supplanted by PSA for screening and early detection. It retains clinical utility in advanced disease, particularly metastatic castration-resistant prostate cancer, where rising PAP can indicate progression when PSA is suppressed by androgen-deprivation therapy. PAP is also a forensic marker in sexual-assault investigations and occasionally rises with prostatic manipulation or benign prostatic disease.
Why is the PAP test ordered?
- Monitoring of metastatic castration-resistant prostate cancer, particularly when PSA levels are suppressed by androgen-deprivation therapy and do not reflect tumour burden
- Evaluation of suspected bone metastases from prostate cancer, where PAP elevation may correlate with skeletal disease when imaging is equivocal
- Assessment of high-grade or poorly differentiated prostate cancer that may produce disproportionately less PSA relative to tumour mass
- Serial monitoring in patients with established prostate cancer who have a historical PAP baseline and for whom trend data add clinical value
- Investigation of unexplained elevation in a patient with known prostatic disease, interpreted alongside PSA, digital rectal examination findings, and imaging
- Correlation with clinical and radiographic response in patients on novel therapies for advanced prostate cancer, where multiple biomarker trends inform treatment decisions
- Forensic and sexual-assault evaluation (non-oncological context), where PAP in body fluids may provide investigative evidence
Sample collection and turnaround
Sample type
Blood (serum)
Fasting required
No
Collection method
Venipuncture at patient service centre
Turnaround
2–4 business days
Collection notes
Phlebotomy at the processing lab's draw site (LabCorp, Quest, or Access Medical Laboratories, depending on routing). Avoid digital rectal examination, ejaculation, or vigorous prostatic manipulation for 48 hours before collection; defer testing for several weeks after prostatic biopsy or transurethral instrumentation. Separate serum promptly; PAP is labile and specimens should be refrigerated or frozen if processing is delayed.
Specimen requirements
Minimum 1 mL serum in a red-top or gel-separator tube. Avoid haemolysis; separate from cells within 1–2 hours and refrigerate or freeze. Note the performing laboratory for serial comparability, as assays and reference ranges differ.
What can affect PAP results?
Mechanical manipulation of the prostate can transiently release PAP into the circulation; ideally blood should be drawn before examination or at least 24–48 hours afterward to avoid spurious elevation.
Instrumentation of the prostate causes substantial and prolonged PAP release; testing should be deferred for several weeks after such procedures.
Non-malignant prostatic disease can modestly raise PAP, reducing specificity; clinical context and imaging help distinguish benign from malignant causes.
PAP is labile and declines rapidly in whole blood or haemolysed samples; serum should be separated promptly and the specimen kept cool or frozen if processing is delayed.
Suppression of androgen signalling reduces prostatic secretory activity and can lower both PSA and PAP; paradoxically rising PAP during treatment suggests progression or castration resistance.
Ejaculation transiently raises serum PAP; patients should abstain for 48 hours before sampling to minimise physiological variation.
What do PAP results mean?
Elevated
Prostate cancer, particularly advanced, metastatic, or bone-metastatic disease; benign prostatic hyperplasia; prostatitis; recent prostatic manipulation or biopsy; and rare non-prostatic sources (some haematological malignancies, Gaucher disease). Very high PAP strongly suggests malignancy, especially when correlated with imaging and PSA.
Normal
Normal PAP does not exclude localised prostate cancer, which may produce minimal circulating enzyme. It is insensitive for early-stage disease and should not be used for screening or case-finding in that context.
Reduced
Low or undetectable PAP is the expected finding in healthy men and in patients with prostate cancer responding to androgen-deprivation therapy. A declining PAP during treatment indicates response; a fall to undetectable levels is favourable.
Note: PAP is less sensitive and less stable than PSA and has been supplanted for most diagnostic purposes. Its primary modern role is in advanced disease and specific monitoring scenarios where PSA alone is insufficient. Serial measurements are more informative than single values, and timing relative to prostatic manipulation or procedures is critical to valid interpretation.
Frequently asked questions
PSA is more sensitive for early prostate cancer, more stable in vitro, and less affected by benign prostatic conditions. PAP remains useful in advanced disease, particularly when androgen-deprivation therapy suppresses PSA but not tumour burden.
How to access the PAP test
The PAP reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: October 7, 2026
Last reviewed: October 7, 2026
- Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer. (2002)
- Taira A, et al. Contemporary role of androgen deprivation therapy for prostate cancer. Oncology (Williston Park). (2010)
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. (2025)
- Vickers AJ, et al. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. (2008)
- Foti AG, et al. Detection of prostatic cancer by solid-phase radioimmunoassay of serum prostatic acid phosphatase. N Engl J Med. (1977)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.
Related tests
male hormones
PSA
The PSA test measures serum prostate-specific antigen, a glycoprotein secreted by prostatic epithelium that rises with glandular disruption from cancer, benign hyperplasia, or inflammation. It is the cornerstone biomarker for prostate cancer screening in shared decision-making and for post-treatment surveillance, interpreted with age, trends, free-to-total ratio, and clinical context.
male hormones
Total Testosterone
The total testosterone test measures the sum of free, albumin-bound, and SHBG-bound testosterone in serum. It is the first-line androgen assessment in males with suspected hypogonadism and in females with hyperandrogenism, requiring morning collection to account for diurnal variation and interpretation alongside SHBG, LH, and FSH to classify androgen disorders.